Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist
Heartburn and acid regurgitation are the cardinal symptoms of gastroesophageal reflux and occur commonly in the Canadian population. Multiple non-prescription treatment options are available for managing these symptoms, including antacids, alginates, histamine-H2 receptor antagonists (H2RAs), and proton-pump inhibitors (PPIs). As a result, pharmacists are ideally positioned to recommend appropriate treatment options based upon an individual’s needs and presenting symptoms, prior treatment response, comorbid medical conditions, and other relevant factors. Individuals who experience mild heartburn and/or have symptoms that occur predictably in response to known precipitating factors can manage their symptoms by avoiding known triggers and using on-demand antacids and/or alginates or lower-dose non-prescription H2RAs (e.g. ranitidine 150 mg). For those with moderate symptoms, lifestyle changes, in conjunction with higher-dose non-prescription H2RAs, may be effective. However, for individuals with moderate-to-severe symptoms that occur frequently (i.e. ≥2 days/week), the non-prescription (Schedule II) PPI omeprazole 20 mg should be considered. The pharmacist can provide important support by inquiring about the frequency and severity of symptoms, identifying an appropriate treatment option, and recognizing other potential causes of symptoms, as well as alarm features and atypical symptoms that would necessitate referral to a physician. After recommending an appropriate treatment, the pharmacist can provide instructions for its correct use. Additionally, the pharmacist should inquire about recurrences, respond to questions about adverse events, provide monitoring parameters, and counsel on when referral to a physician is warranted. Pharmacists are an essential resource for individuals experiencing heartburn; they play a crucial role in helping individuals make informed self-care decisions and educating them to ensure that therapy is used in an optimal, safe, and effective manner.
2. Armstrong D, Marchetti N. Pharmacist-specific guidelines for the medical management of GERD in adults. Can Pharm J (Ott). 2008;141(suppl 1):S10-S15.
3. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrilas PJ, Mayrand S, Moayyedi P, Paterson WG, Sadowski D, van Zanten SJ; Canadian Association of Gastroenterology GERD Consensus Group.Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005;19(1):15-35.
4. Understanding gastroesophogeal reflux disease (GERD). Available at http://www.cdhf.ca/bank/document_en/12understanding-gerd-.pdf (accessed May 25, 2016).
5. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47(1):225-235.
6. Alameel T, Basheikh M, Andrew MK. Digestive symptoms in older adults: prevalence and associations with institutionalization and mortality. Can J Gastroenterol. 2012;26(12):881-884.
7. Wahlqvist P, Guyatt GH, Armstrong D, Degl'Innocenti A, Heels-Ansdell D, El-Dika S, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van ZS, Austin P, Barkun AN, Chiba N, Schunemann HJ. The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validation. Pharmacoeconomics. 2007;25(5):385-396.
8. Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35(11):1257-1266. doi: 10.1111/j.1365-2036.2012.05086.x
9. Jones R, Ballard K. Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. Eur J Gastroenterol Hepatol. 2008;20(4):269-275. doi: 10.1097/MEG.0b013e3282f2a5bd
10. Willemsen KR, Harrington G. From patient to resource: the role of self-care in patient-centered care of minor ailments. SelfCare. 2012;3(3):43-55.
11. Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 2015;37(5):709-716. doi: 10.1007/s11096-015-0150-z
12. Frankel GE, Austin Z. Responsibility and confidence: identifying barriers to advanced pharmacy practice. Can Pharm J (Ott). 2013;146(3):155-161.
13. Taylor J, Landry E, Lalonde L, Tsuyuki RT. Results of a national survey on over-the-counter medicines, Part 1: Pharmacist opinion on current scheduling status. Can Pharm J (Ott). 2012;145(1):40-44.
14. Lalonde L, Tsuyuki RT, Landry E, Taylor J. Results of a national survey on OTC medicines, Part 2: Do pharmacists support switching prescription agents to over-the-counter status? Can Pharm J (Ott). 2012;145(2):73-76.
15. Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, Guarner F, Katelaris P, Smout A, Umar M, Whorwell P, Johanson J, Saenz R, Besançon L, Ndjeuda E, Horn J, Hungin P, Jones R, Krabshuis J, LeMair A; World Gastroenterology Organisation. Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013. J Clin Gastroenterol. 2014;48(7):567-578. doi: 10.1097/MCG.0000000000000141
16. University of Saskatchewan. Pharmacist assessment - GERD. Available at http://medsask.usask.ca/documents/pdfs/GERD_assessment_FINAL.pdf (accessed May 12, 2016).
17. Marchetti N, Chan L. Pharmacist guidelines for the management of GERD in adults: opportunities for practice change under B.C.'s protocol for medication management (PPP # 58). Available at: http://www.canadianhealthcarenetwork.ca/files/2009/12/CE_GERD_BC.8web.pdf (accessed May 12, 2016).
18. Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain? Br J Clin Pharmacol. 2007;64(1):83-89. doi: 10.1111/j.1365-2125.2007.02851.x
19. Lazenby JP, Guzzo MR, Harding SM, Patterson PE, Johnson LF, Bradley LA. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest. 2002;121(2):625-634.
20. Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005 Oct;100(10):2324-2337.
21. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328; quiz 329. doi: 10.1038/ajg.2012.444
22. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32(10):965-973.
23. Coping with common GI symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort. Available at http://www.worldgastroenterology.org/assets/export/userfiles/2013_FINAL_Common%20GI%20Symptoms%20_long.pdf (accessed May 25, 2016).
24. Olex [product monograph]. Montreal, Quebec, Canada: Pendopharm, Division of Pharmascience Inc.; 2014.
25. Battling the burn. Available at http://www.familyhealthonline.ca/fho/pharmacycare/PC_heartburn_FHc08.asp (accessed May 25, 2016).
26. Famotidine Labelling Standard. Available at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/label-etiquet-pharm/famotidi-eng.php (accessed May 18, 2016).
27. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359(16):1700-1707. doi: 10.1056/NEJMcp0804684
28. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376-382. doi: 10.1038/ajg.2012.466
29. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211.
30. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243-1250. doi: 10.1111/j.1572-0241.2005.41703.x
31. Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12(8):837-842.
32. Khan BA, Sodhi JS, Zargar SA, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012;27(6):1078-1082. doi: 10.1111/j.1440-1746.2011.06968.x
33. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(4):372-378; quiz 367. doi: 10.1016/j.cgh.2008.11.021
34. Emerenziani S, Zhang X, Blondeau K, Silny J, Tack J, Janssens J, Sifrim D. Gastric fullness, physical activity, and proximal extent of gastroesophageal reflux. Am J Gastroenterol. 2005;100(6):1251-1256.
35. Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, Takahashi Y, Takeuchi C, Niimi K, Ono S, Kodashima S, Minatsuki C, Fujishiro M, Mitsushima T, Koike K. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med. 2012;10:45. doi: 10.1186/1741-7015-10-45
36. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135-153. doi: 10.1016/j.phrs.2008.09.016
37. National Drug Schedule. Available at http://napra.ca/pages/Schedules/Search.aspx (accessed May 25, 2016).
38. Losec [product monograph]. Mississauga, Ontario: AstraZeneca Canada Inc; 2015.
39. Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, Layer P, Malfertheiner P, Holtmann G. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226-234. doi: 10.1159/000235953
40. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;(5):CD002095. doi: 10.1002/14651858.CD002095.pub5
41. Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31(7):1309-1318. doi: 10.1185/03007995.2015.1047745
42. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-211. doi: 10.1007/s40264-014-0144-0
43. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-534.
44. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267-1272.
45. Hassan-Alin M, Andersson T, Niazi M, Rohss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol. 2005;60(11):779-784.
46. Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001;15(10):1563-1569.
47. Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105-112.
48. Peura DA, Traxler B, Kocun C, Lind T. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014;126(4):33-41. doi: 10.3810/pgm.2014.07.2781
49. Aimi M, Komazawa Y, Hamamoto N, Yamane Y, Furuta K, Uchida Y, Yano S, Morita M, Oguro H, Miyake T, Sugimoto T, Nagi S, Naora K, Goubaru Y, Ishihara S, Kinoshita Y. Effects of omeprazole on sleep disturbance: randomized multicenter double-blind placebo-controlled trial. Clin Transl Gastroenterol. 2014;5:e57. doi: 10.1038/ctg.2014.8
50. Johnson DA, Le Moigne A, Hugo V, Nagy P. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in 2 randomized, double-blind, controlled trials. Curr Med Res Opin. 2015;31(2):243-250. doi: 10.1185/03007995.2014.991818
51. Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, Langstrom G, Jahreskog M, Eklund S, Lind T, Lundell L. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162-1174. doi: 10.1111/apt.13194
52. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and the risk of chronic kidney Disease. JAMA Intern Med. 2016;176(2):238-246. doi: 10.1001/jamainternmed.2015.7193
53. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general Population. PLoS One. 2015;10(6):e0124653. doi: 10.1371/journal.pone.0124653
54. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-416. doi: 10.1001/jamaneurol.2015.4791
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.